Projects
A la primera edición de ATMP Catalyst se han seleccionado seis proyectos innovadores de terapias avanzadas para participar en el programa. Estas iniciativas en fase inicial tienen un alto potencial de transferencia e impacto, y recibirán apoyo personalizado para acelerar su desarrollo y acercarlas al mercado.
Proyectos seleccionados en 2025
Seis proyectos en fase inicial de terapias avanzadas han sido seleccionados para la primera edición de ATMP Catalyst. Todos están ubicados en Cataluña y trabajan en niveles TRL 2–3, con el objetivo de validar su tecnología y avanzar en el desarrollo preclínico y regulatorio. ¡Descúbrelos!
THOR
This project is developing a modular universal CAR-T system that combines a second-generation CAR with a bispecific switch, initially targeting glioblastoma. The design enables flexibility in addressing various tumor types without redesigning the CAR structure, offering significant potential for application in oncology and autoimmune diseases.
Phagocytic Synthetic Cells
Focused on combatting multidrug-resistant respiratory infections in cystic fibrosis patients, this project is developing synthetic cells inspired by natural phagocytosis. These cells engulf and eliminate bacteria directly in the airways without antibiotics, helping prevent resistance and offering a breakthrough for vulnerable patients.
CARcoma
The CARCOMA project targets metastatic sarcomas with novel CAR-T cells engineered to secrete a mutated Fc TIM3 decoy. This approach addresses an unmet clinical need by enhancing T-cell function and persistence in challenging tumor environments.
NoctuRNA
This project pioneers’ circular RNA-based therapies to treat currently incurable diseases. These innovative molecules target critical RNA secondary structures involved in infectious and genetic disorders, opening new therapeutic frontiers.
Spes Immunotherapies
Spes develops personalized cancer vaccines for patients with acute leukemia. Their patented TCR-based platform designs individualized vaccines that match each patient’s specific genetic mutations, aiming to improve immune responses and prevent relapse. Their first candidate focuses on acute lymphoblastic leukemia (ALL), with plans to expand into other leukemias and solid tumors.
FORCE
FORCE is developing an ex vivo platform that enhances mitochondrial transfer from healthy donor T cells to patient-derived T cells. This restores mitochondrial function and reduces mutational load, with potential applications in mitochondrial diseases, cancer immunotherapy, and age-related immune decline.